Hepatic and Overall Progression-Free Survival After Percutaneous Hepatic Perfusion (PHP) as First-Line or Second-Line Therapy for Metastatic Uveal Melanoma-Reference-Cited by-同舟云学术

Hepatic and Overall Progression-Free Survival After Percutaneous Hepatic Perfusion (PHP) as First-Line or Second-Line Therapy for Metastatic Uveal Melanoma

Published:2024-08-22 Issue: Volume: Page:
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Ghali Helana,Dugan Michelle M.,Aflatooni Shaliz,Boby Aleena,DePalo Danielle K.,Laborde José,Choi Junsung,Ahmed Altan F.,Zager Jonathan S.^ORCID

Funder

Provectus

Delcath Systems

SWOG

Philogen

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1245/s10434-024-16039-5.pdf

Reference35 articles.

1. Singh AD, Shields CL, Shields JA. Prognostic factors in uveal melanoma. Melanoma Res. 2001;11(3):255–63. https://doi.org/10.1097/00008390-200106000-00007.

2. Singh AD, Topham A. Incidence of uveal melanoma in the United States: 1973–1997. Ophthalmology. 2003;110(5):956–61. https://doi.org/10.1016/S0161-6420(03)00078-2.

3. Inskip PD, Devesa SS, Fraumeni JF Jr. Trends in the incidence of ocular melanoma in the United States, 1974–1998. Cancer Causes Control. 2003;14(3):251–7. https://doi.org/10.1023/a:1023684502638.

4. Burr JM, Mitry E, Rachet B, Coleman MP. Survival from uveal melanoma in England and Wales 1986 to 2001. Ophthalmic Epidemiol. 2007;14(1):3–8. https://doi.org/10.1080/09286580600977281.

5. Kujala E, Mäkitie T, Kivelä T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44(11):4651–9. https://doi.org/10.1167/iovs.03-0538.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ASO Author Reflections: Optimizing Line of Therapy with the Melphalan/Hepatic Delivery System for Metastatic Uveal Melanoma;Annals of Surgical Oncology;2024-08-28